Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that Johnson & Johnson/Basilea's ceftobiprole, the first anti-methicillin-resistant Staphylococcus aureus cephalosporin to reach the market, will achieve sales of nearly $500 million by 2015 for the treatment of hospital-acquired infections.

The new Pharmacor report Hospital-Acquired Infections finds that ceftobiprole will achieve wide uptake in early lines of therapy, owing to its broad-spectrum activity that includes coverage of methicillin-resistant Staphylococcus aureus, its favorable safety profile, and physician familiarity with the cephalosporin drug class.

The report also finds that the late-stage pipeline for hospital-acquired infections is dominated by narrow-spectrum agents -- such as Theravance/Astella's telavancin, Targanta's oritavancin, and Pfizer's dalbavancin -- that target difficult-to-treat gram-positive infections, particularly those caused by methicillin-resistant Staphylococcus aureus. Product differentiation will be difficult but essential to the commercial success of these competing therapies in the major pharmaceutical markets (the United States, Japan, Germany, France, Spain, Italy, and the United Kingdom).

"The treatment of hospital-acquired infections is a mature and highly competitive market that is crowded with effective, well-established antibacterial agents," said Sylvia Eash, Ph.D., analyst at Decision Resources. "Near-term opportunity lies in developing therapies that offer activity against key resistant gram-positive and gram-negative pathogens, which are smaller subsets of the market that have a high unmet clinical need."

About Hospital-Acquired Infections

Hospital-acquired infections are a source of significant morbidity, mortality, and economic cost, and they represent the most active clinical areas for antibacterial drug development. Studies estimate mortality rates of up to 15% and show that bloodstream infections or pneumonia contracted in the hospital can add up to 26 days to the length of stay.

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563

Sierra Health Services Extends National Reach While Focusing on In-State Growth

View Now